Prelude Therapeutics (PRLD) Return on Sales (2024 - 2026)

Prelude Therapeutics (PRLD) has 3 years of Return on Sales data on file, last reported at 0.08% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales changed N/A year-over-year to 0.08%; the trailing twelve-month figure through Mar 2026 stood at 0.09% (changed N/A YoY), and the FY2025 full-year result was 0.26%, up 20.0% from the prior year.
• Return on Sales retreated to 0.08% in Q1 2026, from 0.03% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.03% in Q4 2025 to a low of 0.25% in Q3 2024.
• A 3-year average of 0.1% and a median of 0.08% in 2026 frame the typical range for Return on Sales.
• Peak annual rise in Return on Sales reached 19 bps in 2025, while the deepest fall reached 5 bps in 2025.
• Tracing PRLD's Return on Sales over 3 years: stood at 0.09% in 2024, then surged by 63 bps to 0.03% in 2025, then tumbled by 135 bps to 0.08% in 2026.
• Business Quant data shows PRLD's Return on Sales at 0.08% in Q1 2026, 0.03% in Q4 2025, and 0.06% in Q3 2025.